Impact of the PPAR-γ2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: Evidence from BENEDICT

Diabetes

Volumn 58, Issue 12, 2009, Pages 2920-2929

  De Cosmo, Salvatore ^a   Motterlini, Nicola ^b   Prudente, Sabrina ^a   Pellegrini, Fabio ^a   Trevisan, Roberto ^c   Bossi, Antonio ^d   Remuzzi, Giuseppe ^b,c   Trischitta, Vincenzo ^a,e   Ruggenenti, Piero ^b,c  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c OSPEDALI RIUNITI   (Italy)

^d TREVIGLIO HOSPITAL   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALANINE; ALBUMIN; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; GENOMIC DNA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PLACEBO; PROLINE; TRANDOLAPRIL; VERAPAMIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; ALBUMIN BLOOD LEVEL; ALLELE; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HAZARD RATIO; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; URINALYSIS; URINARY EXCRETION; AGED; ALBUMINURIA; BLOOD PRESSURE; DIABETES MELLITUS; DRUG EFFECT; GENETIC PREDISPOSITION; GENETICS; ITALY; KAPLAN MEIER METHOD; METHODOLOGY; MIDDLE AGED; RISK FACTOR;

ADULT; AGED; ALANINE; ALBUMINURIA; ALLELES; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HOMOZYGOTE; HUMANS; HYPERTENSION; INCIDENCE; ITALY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA; PROLINE; PROSPECTIVE STUDIES; RESEARCH DESIGN; RISK FACTORS;

EID: 73249137608     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db09-0407     Document Type: Article

References (34)

1. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982;1:1430-1432
2. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS. Urinary albumin excretion: an independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999;19:1992-1997
3. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002;106:1777-1782
4. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Scharling H, Appleyard M, Jensen JS. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004;110:32-35
5. Arnlov J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, Benjamin EJ, D'Agostino RB, Vasan RS. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005;112:969-975
6. Wang TJ, Evans JC, Meigs JB, Rifai N, Fox CS, D'Agostino RB, Levy D, Vasan RS. Low-grade albuminuria and the risks of hypertension and blood pressure progression. Circulation 2005;111:1370-1376
7. Ruggenenti P, Remuzzi G. Time to abandon microalbuminuria? Kidney Int 2006;70:1214-1222
8. Forman JP, Brenner BM. 'Hypertension' and 'microalbuminuria': the bell tolls for thee. Kidney Int 2006;69:22-28
9. Gansevoort RT, Verhave JC, Hillege HL, Burgerhof JG, Bakker SJ, de Zeeuw D, de Jong PE. The validity of screening based on spot morning urine samples to detect subjects with microalbuminuria in the general population. Kidney Int Suppl 2005;S28-S35
10. Asselbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM, Voors AA, de Zeeuw D, de Jong PE, van Veldhuisen DJ, van Gilst WH. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004;110:2809-2816
11. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-2446
12. Ruggenenti P, Perna A, Ganeva M, Ene-Iordache B, Remuzzi G. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. J Am Soc Nephrol 2006;17:3472-3481
13. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-1951
14. Parving H-H, Mauer M, Ritz E: Diabetic nephropathy. In Brenner & Rector's The Kidney. 7th ed. Brenner BM, Ed. Philadelphia, Saunders, 2004, p. 1777-1818
15. Eurich DT, Majumdar SR, Tsuyuki RT, Johnson JA. Reduced mortality associated with the use of ACE inhibitors in patients with type 2 diabetes. Diabetes Care 2004;27:1330-1334
16. Orchard TJ, Chang YF, Ferrell RE, Petro N, Ellis DE. Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study. Kidney Int 2002;62:963-970
17. Mykkanen L, Zaccaro DJ, Wagenknecht LE, Robbins DC, Gabriel M, Haffner SM. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. Diabetes 1998;47:793-800
18. De Cosmo S, Minenna A, Ludovico O, Mastroianno S, Di Giorgio A, Pirro L, Trischitta V. Increased urinary albumin excretion, insulin resistance, and related cardiovascular risk factors in patients with type 2 diabetes: evidence of a sex-specific association. Diabetes Care 2005;28:910-915
19. Parvanova AI, Trevisan R, Iliev IP, Dimitrov BD, Vedovato M, Tiengo A, Remuzzi G, Ruggenenti P. Insulin resistance and microalbuminuria: a cross-sectional, case-control study of 158 patients with type 2 diabetes and different degrees of urinary albumin excretion. Diabetes 2006;55:1456-1462
20. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L, Lander ES. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000;26:76-80
21. Almind K, Doria A, Kahn CR. Putting the genes for type II diabetes on the map. Nat Med 2001;7:277-279
22. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J. A Pro12Ala substitution in PPAR-gamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998;20:284-287
23. Poulsen P, Andersen G, Fenger M, Hansen T, Echwald SM, Volund A, Beck-Nielsen H, Pedersen O, Vaag A. Impact of two common polymorphisms in the PPARgamma gene on glucose tolerance and plasma insulin profiles in monozygotic and dizygotic twins: thrifty genotype, thrifty phenotype, or both? Diabetes 2003;52:194-198
24. Tonjes A, Scholz M, Loeffler M, Stumvoll M. Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals. Diabetes Care 2006;29:2489-2497
25. Ludovico O, Pellegrini F, Di Paola R, Minenna A, Mastroianno S, Cardellini M, Marini MA, Andreozzi F, Vaccaro O, Sesti G, Trischitta V. Heterogeneous effect of peroxisome proliferator-activated receptor gamma2 Ala12 variant on type 2 diabetes risk. Obesity (Silver Spring) 2007;15:1076-1081
26. Morini E, Tassi V, Capponi D, Ludovico O, Dallapiccola B, Trischitta V, Prudente S. Interaction between PPARgamma2 variants and gender on the modulation of body weight. Obesity (Silver Spring) 2008;16:1467-1470
27. Herrmann SM, Ringel J, Wang JG, Staessen JA, Brand E. Peroxisome proliferator-activated receptor-gamma2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: The Berlin Diabetes Mellitus (BeDiaM) Study. Diabetes 2002;51:2653-2657
28. Caramori ML, Canani LH, Costa LA, Gross JL. The human peroxisome proliferator-activated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes. Diabetes 2003;52:3010-3013
29. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990;347:645-650
30. Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 1996;39:665-668
31. Mori H, Ikegami H, Kawaguchi Y, Seino S, Yokoi N, Takeda J, Inoue I, Seino Y, Yasuda K, Hanafusa T, Yamagata K, Awata T, Kadowaki T, Hara K, Yamada N, Gotoda T, Iwasaki N, Iwamoto Y, Sanke T, Nanjo K, Oka Y, Matsutani A, Maeda E, Kasuga M. The Pro123Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 2001;50:891-894
32. Bennett CD, Campbell MN, Cook CJ, Eyre DJ, Nay LM, Nielsen DR, Rasmussen RP, Bernard PS. The LightTyper: high-throughput genotyping using fluorescent melting curve analysis. Biotechniques 2003;34:1288-1292, 1294-1295
33. Dell'Omo G, Penno G, Del Prato S, Pedrinelli R. Doxazosin in metabolically complicated hypertension. Expert Rev Cardiovasc Ther 2007;5:1027-1035
34. Bakris GL, Ruilope LM, McMorn SO, Weston WM, Heise MA, Freed MI, Porter LE. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens 2006;24:2047-2055